Canntab Therapeutics Limited (CTABF)
- Previous Close
0.0073 - Open
0.0073 - Bid --
- Ask --
- Day's Range
0.0073 - 0.0073 - 52 Week Range
0.0016 - 0.0210 - Volume
2,000 - Avg. Volume
883 - Market Cap (intraday)
284,037 - Beta (5Y Monthly) 1.43
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Mar 8, 2016
- 1y Target Est
--
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.
canntab.ca--
Full Time Employees
May 31
Fiscal Year Ends
Sector
Recent News: CTABF
Performance Overview: CTABF
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CTABF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CTABF
Valuation Measures
Market Cap
284.04k
Enterprise Value
1.66M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.29
Price/Book (mrq)
--
Enterprise Value/Revenue
22.59
Enterprise Value/EBITDA
-0.86
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-69.60%
Return on Equity (ttm)
--
Revenue (ttm)
73.48k
Net Income Avi to Common (ttm)
-3.36M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
16.81k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-612.49k
Company Insights: CTABF
CTABF does not have Company Insights